DURECT CORP. DL-001 (F:DC8A) — Market Cap & Net Worth
Market Cap & Net Worth: DURECT CORP. DL-001 (DC8A)
DURECT CORP. DL-001 (F:DC8A) has a market capitalization of $50.69 Million (€43.36 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #21830 globally and #1940 in its home market, demonstrating a -0.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DURECT CORP. DL-001's stock price €1.60 by its total outstanding shares 31054187 (31.05 Million).
DURECT CORP. DL-001 Market Cap History: 2015 to 2025
DURECT CORP. DL-001's market capitalization history from 2015 to 2025. Data shows change from $72.87 Million to $58.09 Million (-1.35% CAGR).
DURECT CORP. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DURECT CORP. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DC8A by Market Capitalization
Companies near DURECT CORP. DL-001 in the global market cap rankings as of May 5, 2026.
Key companies related to DURECT CORP. DL-001 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #497 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #531 globally with a market cap of $49.66 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #571 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #497 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #531 | Zoetis Inc | NYSE:ZTS | $49.66 Billion | $112.68 |
| #571 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.87 |
DURECT CORP. DL-001 Historical Marketcap From 2015 to 2025
Between 2015 and today, DURECT CORP. DL-001's market cap moved from $72.87 Million to $ 58.09 Million, with a yearly change of -1.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €58.09 Million | +81.82% |
| 2024 | €31.95 Million | +67.62% |
| 2023 | €19.06 Million | -83.05% |
| 2022 | €112.47 Million | +271.02% |
| 2021 | €30.32 Million | -50.59% |
| 2020 | €61.36 Million | -40.91% |
| 2019 | €103.83 Million | +529.96% |
| 2018 | €16.48 Million | -40.96% |
| 2017 | €27.92 Million | -37.33% |
| 2016 | €44.55 Million | -38.86% |
| 2015 | €72.87 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of DURECT CORP. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.69 Million USD |
| MoneyControl | $50.69 Million USD |
| MarketWatch | $50.69 Million USD |
| marketcap.company | $50.69 Million USD |
| Reuters | $50.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DURECT CORP. DL-001
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more